Li Yi, Zou Tongjuan, Zeng Xueying, Qin Yao, Zhou Ran, Cao Lianghai, Hu Jian, Lei Xianying, Dong Qionglan, Qin Yiwei, Zhang Ge, Kang Yan, Wang Bo, Zhang Zhongwei, Wang Xiaoting, Chao Yangong, Yin Wanhong
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, PR China.
Department of Critical Care Medicine, Chengdu Integrated TCM & Western Medicine Hospital, Chengdu First People's Hospital, PR China.
Eur J Intern Med. 2025 Mar;133:39-47. doi: 10.1016/j.ejim.2024.12.007. Epub 2024 Dec 26.
The purpose of this study was to determine whether our new thinking guidance named OPACCUS (oxygen metabolism, perfusion, arterial tension, cardiac output, systemic congestion, unregulated host response and search for inciting illness event) with 7 questions you need to ask before shock therapy and evidences provided by critical ultrasound considering hemodynamics, the unregulated host response and inciting illness event would improve mortality in shock patients.
A multicenter, prospective, observational cohort study.
Intensive care units of 20 hospitals in Southwest China.
Shock patients between October 2022 and February 2024 were divided into three groups, namely, the full-compliance group (n = 171), moderate-compliance group (n = 149) and low-compliance group (n = 220), according to the compliance rate with the OPACCUS guidance.
Adoption of the OPACCUS guidance in every repeat assessment MEASUREMENTS AND MAIN RESULTS: Demographics, clinical information, hemodynamics parameters and critical care ultrasound evaluations were recorded. The primary outcome was all-cause mortality within 30 days. A total of 540 patients completed the study and were ultimately included in the analysis. After multivariate regression adjustment, the 30-day mortality of shock patients in the full-compliance group (21.05 %) was significantly lower than that in the low-compliance group (36.82 %) (HR=1.646*, RMST=-3.223*). Restricted mean survival time (RMST) univariate analysis showed that the higher the OPACCUS compliance rate was, the longer the survival time. ICU and hospital costs were lower in the full-compliance group than in the moderate-compliance group.
Compliance to the new OPACCUS guidance could improve 30-day mortality and reduce costs for shock patients.
ClinicalTrials.gov Identifier: ChiCTR2200061952. Registration date: 13/07/2022.
本研究旨在确定我们新的思维指导方法OPACCUS(氧代谢、灌注、动脉张力、心输出量、全身充血、不受控制的宿主反应以及寻找诱发疾病事件),即在休克治疗前需要提出的7个问题,以及由考虑血流动力学、不受控制的宿主反应和诱发疾病事件的重症超声提供的证据,是否能提高休克患者的死亡率。
一项多中心、前瞻性、观察性队列研究。
中国西南部20家医院的重症监护病房。
2022年10月至2024年2月期间的休克患者根据对OPACCUS指导的依从率分为三组,即完全依从组(n = 171)、中度依从组(n = 149)和低度依从组(n = 220)。
在每次重复评估中采用OPACCUS指导
记录人口统计学、临床信息、血流动力学参数和重症监护超声评估结果。主要结局为30天内全因死亡率。共有540例患者完成研究并最终纳入分析。经过多变量回归调整后,完全依从组休克患者的30天死亡率(21.05%)显著低于低度依从组(36.82%)(HR=1.646*,RMST=-3.223*)。受限平均生存时间(RMST)单变量分析显示,OPACCUS依从率越高,生存时间越长。完全依从组的重症监护病房和医院费用低于中度依从组。
遵循新的OPACCUS指导可提高休克患者的30天死亡率并降低费用。
ClinicalTrials.gov标识符:ChiCTR2200061952。注册日期:2022年7月13日。